Tab-cel® (tabelecleucel)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
RR EBV+ PTLD following HCT
RR EBV+ PTLD following SOT
Nasopharyngeal carcinoma (NPC)
EBV+ cancers
Multiple Sclerosis (MS)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Autologous ATA190: Progressive MS
Off-the-shelf, allogeneic ATA188: Progressive MS
Next-Generation CAR T Pipeline
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA2271: Solid tumors
ATA2321: Acute myeloid leukemia
ATA2431: B-cell malignancies
ATA3219: Off-the-shelf, allogeneic B-cell malignancies
Autoimmune disease CAR T program
Infectious disease CAR T program
Other Programs
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA230: Refractory CMV Infection and Disease Post HCT/SOT
ATA520: Hematologic malignancies
ATA621: JCV PML and BKVAN
ATA368: HPV associated cancers